Clinical Trial Update: Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety study evaluating MT-6548 in adults with anemia associated with chronic kidney disease requiring hemodialysis in Japan has completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• MT-6548

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Anemia; Hemodialysis Dependent Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-04-12